Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$1.53 USD
-0.16 (-9.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.53 USD
-0.16 (-9.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 10% and 69.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inotiv (NOTV) delivered earnings and revenue surprises of -122.22% and 14.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 29.41% and 14.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Taysha Gene Therapies, Inc. (TSHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Believe Taysha Gene Therapies, Inc. (TSHA) Could Rally 608%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 608.2% upside potential for Taysha Gene Therapies, Inc. (TSHA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Company News for Apr 13, 2021
by Zacks Equity Research
Companies in the news are: NUAN, TSHA, CADE, NVDA